AliveCor teams up with PulseAI to integrate cardiac software
The tie-up brings newly cleared algorithmic heart-rhythm analysis to consumer wearables.

Screenshot: alivecor.com
AliveCor has entered a strategic partnership with software developer PulseAI to integrate automated heart-rhythm interpretation directly into its Kardia app [0]. This integration marks a shift in how consumer wearables manage diagnostic data, moving from simple activity tracking toward clinical-grade, regulatory-cleared health analysis [0]. Under the agreement, AliveCor aims to offer users enhanced cardiac evaluations using algorithms designed for wearable hardware [1].
PulseAI develops software for cardiovascular monitoring and secured clearance from the US Food and Drug Administration for its PulseAPI SmartWatch platform on Oct. 27, 2026 [1]. The software integration is scheduled to roll out to consumer devices in the first half of 2027 [1]. Priya Abani, CEO of AliveCor, noted that the collaboration focuses on delivering "clinically actionable data" [1] alongside Alan Kennedy, CEO of PulseAI [1].
PulseAI previously secured an undisclosed seed round on Jan. 12, 2026, in a financing led by Innovation Ulster, with additional backing from The Mortara Group and The Francis Crick Institute [1]. AliveCor produces hardware and algorithmic software for mobile electrocardiograms, expanding wearable capabilities into clinical health analysis [1].
Questions and answers
When will the integrated Kardia features launch?
The integrated features are slated to debut in the first half of 2027.
What regulatory clearance did PulseAI receive?
PulseAI received clearance from the FDA for its PulseAPI SmartWatch software on Oct. 27, 2026.
Companies & investors in this story
Sources
- 1.Smartwatch ECG AI Deal: AliveCor Plans Premature-Beat Checks for Apple Watch Only — techtimes.com, Nov 17, 2026
- 2.The Decentralized Clinic: AI ECGs Transform the Smartwatch Market — BriefGlance, Nov 16, 2026
